News stories about Asterias Biotherapeutics (NYSE:AST) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Asterias Biotherapeutics earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Asterias Biotherapeutics Inc (AST) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- Zacks: Brokerages Set $8.88 Target Price for Asterias Biotherapeutics Inc (AST) (americanbankingnews.com)
- Analysts Expect Asterias Biotherapeutics Inc (NYSE:AST) to Post ($0.18) EPS (americanbankingnews.com)
- $1.85 Million in Sales Expected for Asterias Biotherapeutics Inc (NYSE:AST) This Quarter (americanbankingnews.com)
Shares of Asterias Biotherapeutics (NYSE AST) traded down 1.43% during mid-day trading on Tuesday, reaching $3.45. The company had a trading volume of 50,466 shares. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.50. Asterias Biotherapeutics has a one year low of $2.54 and a one year high of $5.80. The firm’s market capitalization is $169.96 million.
Several analysts recently commented on AST shares. Zacks Investment Research raised Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, July 17th. HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/08/08/asterias-biotherapeutics-ast-getting-somewhat-favorable-media-coverage-study-shows-updated-updated-updated.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.